Report Highlights

The United States' Role in Global Oxygen Therapy Device Supply Chains

The United States is the largest single national market for home oxygen therapy equipment but a net importer of finished concentrators and cylinder components. Imports under HS 9019.20 are dominated by China, which supplies the majority of low-cost portable oxygen concentrators, with Mexico growing as a nearshore assembly base for domestic brands. American firms such as Inogen and Chart Industries design and sell high-value units, yet component sourcing for molecular sieve beds and compressors remains concentrated in Asia.

Finished concentrators typically enter through the ports of Los Angeles and Long Beach, then move by truck and rail to regional third-party warehouses in Texas, Georgia, and Tennessee. Liquid medical oxygen, by contrast, is produced domestically by Linde and Air Liquide across dozens of air separation plants, insulating bulk supply from import shocks. The vulnerability sits in the device layer, where a single shipping disruption from Shenzhen can stall home-care fulfillment for several weeks.

Growth Drivers for American Oxygen Therapy Device Trade and Production

Three forces are expanding domestic demand and production. Over four million Americans turn 65 each year, and COPD remains the leading indication for home oxygen, sustaining rental volumes across Medicare Part B. Hospital discharge pressure has shifted patients toward home concentrators, lifting unit volumes for distributors such as AdaptHealth and the Apria network owned by Owens & Minor. Each new home placement also generates recurring demand for filters, tubing, and cannulas, a second revenue stream that domestic suppliers are capturing.

Import substitution is the second driver, and Section 301 duties on Chinese-origin concentrators are accelerating it. Distributors are qualifying Mexico-assembled units under USMCA, which lifts nearshore output in Tijuana and Reynosa and shortens transit to Texas distribution centers. Inogen's Goleta, California engineering center keeps design and quality control onshore. Lithium battery packs for portable units remain largely imported, making battery sourcing the third driver to watch as lighter devices gain share.

Supply Chain Risks and Trade Barriers

Component dependency is the most acute risk. Zeolite molecular sieve, the adsorbent at the core of every pressure swing adsorption concentrator, is sourced predominantly from China, and compressor modules come largely from Asian suppliers. A single disruption in either input can halt assembly across several U.S. and Mexican plants, with replacement sieve bed lead times stretching well beyond a standard production cycle.

Regulatory and logistics exposure compounds the risk. The 2021 Philips Respironics recall of roughly 5.5 million sleep and respiratory devices showed how a single FDA enforcement action can strip capacity from Medicare-contracted fulfillment networks. Port congestion at Los Angeles and Long Beach, combined with Section 301 duties on Chinese-origin units, raises landed costs, while peso-denominated Mexican assembly exposes manufacturers to USD/MXN currency swings.

Trade and Investment Opportunities in U.S. Oxygen Therapy Devices

Export opportunity lies in high-value portable concentrators. U.S. manufacturers can target Canada, where provincial home oxygen programs are expanding, and Gulf Cooperation Council states, which are investing heavily in home-care infrastructure. Companies with FDA-cleared, USMCA-compliant units can serve these markets from existing Texas and Mexico lines, and Inogen's established international distribution network provides a ready commercial channel.

Inbound foreign direct investment should target domestic battery pack and sieve bed assembly. Investors establishing 40,000-square-foot facilities near Dallas-Fort Worth or Memphis would benefit from interstate logistics that reach a large share of the U.S. population within a one-day truck drive. Such plants would substitute for Asian imports exposed to Section 301 duties, and strategic buyers including Chart Industries and Drive DeVilbiss Healthcare are positioned to anchor them.

Market at a Glance

Leading Market Participants

• Inogen
• Philips Respironics
• ResMed
• Drive DeVilbiss Healthcare
• Chart Industries
• Invacare
• Linde Healthcare
• Air Liquide Healthcare
• Medline Industries
• Vyaire Medical

Regulatory and Trade Policy Environment

The regulatory framework is anchored by FDA 510(k) clearance for oxygen concentrators and by Medicare's Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) benefit, which sets payment and supplier standards under Part B. CMS competitive bidding determines which suppliers win contracts in designated regions, so bid outcomes shape distributor volumes directly. Supplier accreditation requirements add compliance costs for new entrants.

Trade policy runs through USMCA and Section 301. USMCA eliminates tariffs on qualifying Mexican-assembled concentrators, while Section 301 List 1 and List 3 duties of 25 percent apply to many Chinese-origin respiratory products classified under HTS 9019.20. Foreign acquisitions of domestic device makers undergo CFIUS review, and Buy American preferences in federal procurement favor domestically produced units for VA and military purchasing.

U.S. Oxygen Therapy Device Supply Chain Outlook to 2032

Supply chains will shift toward lighter, battery-powered concentrators and nearshore assembly through 2032. Portable units will gain share over stationary concentrators as payers favor mobility-enabled prescriptions, and assembly volumes in Baja California and Coahuila will rise as tariff exposure on Asian components persists. U.S. firms will retain design and final quality control while Mexican plants handle sub-assembly, and domestic sieve bed production remains the critical gap to close.

Technology changes will alter comparative advantage. Oxygen-generating systems using advanced adsorbents and lower-power compressors reduce reliance on heavy Asian-sourced components, favoring manufacturers that integrate design with domestic electronics suppliers. By 2032, the United States will remain a net importer of finished concentrators but will rely less on China for core modules, reshaping the trade balance toward Mexico and European compressor technology.